ReviewDrug discovery today2021
Drugs acting on the renin-angiotensin system and SARS-CoV-2.
Review in Drug discovery today, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- Significance of nitrosative stress and glycoxidation products in the diagnosis of COVID-19.Scientific reports · 2024Article
- The impact of SARS-CoV-2 infection in patients with cystic fibrosis undergoing CFTR channel modulators treatment: a literature review.Respiratory research · 2023Review
- Review
- Low Molecular Weight Heparin, Anti-inflammatory/Immunoregulatory and Antiviral Effects, a Short Update.Cardiovascular drugs and therapy · 2023Review
- The direct correlation between microbiota and SARS-CoV-2 infectious disease.Inflammopharmacology · 2023Review
- Effects of Vitamin D on the Renin-Angiotensin System and Acute Childhood Pneumonia.Antibiotics (Basel, Switzerland) · 2022Article
- Deciphering the therapeutical potentials of rosmarinic acid.Scientific reports · 2022Article
- Pleiotropic effects of AT-1 receptor antagonists in hypoxia induced by cardiac ischaemia.Inflammopharmacology · 2022Article
- Pharmacotherapy Based on ACE2 Targeting and COVID-19 Infection.International journal of molecular sciences · 2022Article
- Pregnancy and COVID-19, focus on vaccine and pharmacological treatment.Journal of reproductive immunology · 2022Review
- Nanoparticles for Coronavirus Control.Nanomaterials (Basel, Switzerland) · 2022Review
- A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?Immunologic research · 2022Review
- Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection.Molecular biology reports · 2022Article
- Association between COVID-19 and angiotensin-converting enzyme inhibitors with the spotlight on zinc: an opinion.Annals of medicine · 2021Article
- COVID-19 vaccines and decreased transmission of SARS-CoV-2.Inflammopharmacology · 2021Review
- Logistics management provides greater efficiency, governance and compliance.International journal of clinical pharmacy · 2021Article
- Commentary of the mRNA vaccines COVID-19.Asian journal of pharmaceutical sciences · 2021Article
- The advantages of drug treatment with statins in patients with SARS-CoV-2 infection.Wiener klinische Wochenschrift · 2021Review
- Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients.Wiener klinische Wochenschrift · 2021Article
- Brief review of the mRNA vaccines COVID-19.Inflammopharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the ongoing global Coronavirus 2019 (COVID-19) pandemic, resulting in thousands of deaths worldwide and representing a health challenge with few precedents in human history. Angiotensin-converting enzyme 2 (ACE-2) facilitates the access of SARS-CoV-2 to cells. Therapeutic agents acting on the renin-angiotensin system (RAS) might be able to modulate the concentration of ACE-2 and the various components of the system. Here, we discuss current pharmacological, molecular, and clinical evidence to investigate whether drugs acting on RAS with modulation of the ACE-2 concentration have added value in combating SARS-CoV-2 infection. We also highlight the possible deleterious action of the ACE/Ang-II/AT-1r axis and possible beneficial role of the ACE-2/Ang 1-7/MasR axis in acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2, discussing the possibility of addressing the various RAS components with drug treatments to improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.